Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials-Reference-Cited by-同舟云学术

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Published:2022-05-17 Issue:1 Volume:25 Page:630-639
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Tobin Joshua¹^ORCID,Ford Janet H.²,Tockhorn-Heidenreich Antje³,Nichols Russell M.²,Ye Wenyu²,Bhandari Rohit²,Mi Xiaojuan²⁴,Sharma Karan²,Lipton Richard B.⁵

Affiliation:

1. Neurosciences Clinic, Banner University Medical Center, Phoenix, AZ, USA

2. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

3. Eli Lilly and Company, Bracknell, UK

4. TechData Service Company, King of Prussia, PA, USA

5. Albert Einstein College of Medicine, Bronx, NY, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2071528

Reference43 articles.

1. A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

3. Estimating the Economic Burden of Migraine on US Employers

4. Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View

5. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population;The Journal of Headache and Pain;2024-02-12

2. The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders;The Journal of Headache and Pain;2024-01-04

3. Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review;Life;2023-02-28

4. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States;Journal of Medical Economics;2023-01-20